Smart drug schedule may improve melanoma treatment
NCT ID NCT03543969
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 39 times
Summary
This early-phase study tested a new way of giving three drugs (encorafenib, binimetinib, and nivolumab) to people with advanced BRAF-mutant melanoma. Instead of taking the drugs every day, participants followed an on/off schedule to see if it could control the cancer while reducing side effects. The study enrolled 14 adults with stage IIIC-IV melanoma that could not be removed by surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.